GLP-1 Weight Loss Approval: What You Need to Know

Last reviewed: June 6, 2026

Last updated: June 6, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

The FDA has approved several GLP-1 receptor agonist medications specifically for chronic weight management, marking a significant shift in how doctors treat obesity. These medications work by mimicking a natural hormone that signals fullness and regulates appetite, helping patients lose an average of 15–22% of their body weight in clinical trials. PlexusDx connects you with personalized GLP-1 therapy options across all 50 states, with no insurance required.

FDA-Approved GLP-1 Medications for Weight Loss

Two GLP-1 medications currently hold FDA approval specifically for chronic weight management: semaglutide (brand name Wegovy) and tirzepatide (brand name Zepbound). Semaglutide was approved by the FDA in 2021 as the first GLP-1 injectable treatment for weight loss in non-diabetic patients. Tirzepatide received FDA approval in 2023 and represents a dual GLP-1/GIP receptor agonist, targeting two appetite-regulating pathways simultaneously. Both medications demonstrated superior weight loss compared to placebo and lifestyle changes alone in randomized controlled trials.

Liraglutide (Saxenda) also holds FDA approval for weight management and was among the earliest GLP-1 options approved for this indication. The approval process for these medications required extensive clinical evidence showing sustained weight loss benefits and acceptable safety profiles. Patients choosing FDA-approved options benefit from decades of regulatory scrutiny and real-world data collection across millions of users globally.

How GLP-1 Medications Work for Weight Loss

GLP-1 receptor agonists activate receptors in the brain's appetite control centers, particularly the hypothalamus, creating genuine signals of satiety and fullness. This mechanism differs fundamentally from older weight loss medications that relied on stimulation or thermogenesis; instead, GLP-1 drugs normalize the hunger hormones that many overweight patients produce in abnormal patterns. The medication also slows gastric emptying, meaning food stays in the stomach longer, prolonging feelings of satisfaction after meals.

Beyond appetite suppression, GLP-1 agonists improve blood sugar control and reduce inflammation, secondary effects that support metabolic health independent of weight loss. Research shows these medications also lower cardiovascular risk markers including blood pressure and cholesterol levels. Clinical data from semaglutide trials reported not only weight reduction but also decreased progression to type 2 diabetes and reduced cardiovascular events in patients with heart disease risk factors.

Compounded vs. FDA-Approved GLP-1 Options at PlexusDx

PlexusDx offers both FDA-approved and compounded GLP-1 medications from licensed 503A compounding pharmacies, giving patients flexibility based on preference, cost, and availability. Compounded semaglutide and tirzepatide cost significantly less than brand-name versions while containing the identical active pharmaceutical ingredient. The distinction lies in manufacturing: FDA-approved medications undergo brand-name production processes, while compounded versions are created in state-licensed pharmacies under strict pharmaceutical standards.

Compounded Semaglutide Injection starts at $149 monthly, while compounded Tirzepatide Injection begins at $249 monthly—flat pricing regardless of dose escalation. PlexusDx also offers oral formulations, dual-compound options like GLP-Squared Injection, and the Microdose GLP-1 Protocol for patients preferring lower starting doses. All medications are HSA/FSA eligible, and PlexusDx serves all 50 states without requiring insurance or membership fees.

Personalization Through Genetic Testing for GLP-1 Success

Individual response to GLP-1 therapy varies significantly based on genetic factors affecting appetite regulation and metabolic pathways. PlexusDx offers the Precision Peptide Genetic Test, a peptide-pathway genetic assessment examining 14 metabolic pathways, 49 peptides, and 150+ genetic insights that predict medication responsiveness. Key genetic variants analyzed include GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313—genes that directly influence how your body responds to GLP-1 receptor activation.

This genetic testing ($99 after your first month of treatment) helps PlexusDx identify whether you're a strong responder to semaglutide, tirzepatide, or dual-compound therapy, and whether oral or injection formulations align better with your genetic profile. Patients with favorable GLP1R variants often experience greater appetite suppression, while those with certain FTO variants may benefit from higher doses or combination approaches. This precision medicine approach eliminates trial-and-error prescribing and accelerates your path to effective, sustainable weight loss.

Clinical Evidence Supporting GLP-1 Weight Loss Efficacy

The STEP clinical trial program demonstrated that semaglutide produces average weight loss of 14.9% at the 1.0 mg dose and 17.4% at the 2.4 mg dose over 68 weeks in non-diabetic patients with obesity. When semaglutide was discontinued, weight regain occurred, reinforcing that these medications work while you take them—similar to blood pressure medications that require ongoing use. Real-world effectiveness data from pharmacy and insurance claims show results comparable to trial outcomes, with most patients achieving meaningful weight loss within 3–6 months.

Tirzepatide demonstrated even stronger results in the SURMOUNT trials, with average weight loss reaching 20.9% at the highest dose after 72 weeks of treatment. This dual GIP/GLP-1 mechanism produced superior outcomes compared to semaglutide monotherapy in head-to-head analyses. Beyond weight loss, both drug classes reduced hemoglobin A1C, fasting glucose, and triglycerides, providing metabolic benefits independent of body composition changes.

Safety Profile and Side Effects of GLP-1 Therapy

The most common side effects of GLP-1 medications involve the gastrointestinal system: nausea, vomiting, diarrhea, and constipation occur in 20–40% of patients, typically during dose escalation and diminishing over time as the body adapts. Serious adverse events remain rare; the FDA has not identified novel safety signals beyond those observed in clinical trials. Patients with personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 should not use GLP-1 medications due to preclinical animal data.

Rare cases of pancreatitis and gallbladder issues have been reported, though causality remains unclear in many cases given the confounding variable of rapid weight loss itself. Blood pressure sometimes decreases during treatment, requiring monitoring if you take antihypertensive medications. PlexusDx recommends discussing any existing medical conditions with the healthcare provider managing your treatment before beginning therapy.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is semaglutide FDA-approved for weight loss in people without diabetes?

Yes, semaglutide (Wegovy) received FDA approval in 2021 specifically for chronic weight management in non-diabetic adults with obesity or overweight plus related conditions. PlexusDx offers both FDA-approved semaglutide and compounded versions starting at $149 monthly, allowing you to choose based on preference and budget.

How much weight can I expect to lose with GLP-1 treatment?

Clinical trials show average weight loss of 15–22% of body weight over 68–72 weeks, though individual results vary based on genetics, adherence, and lifestyle factors. The Precision Peptide Genetic Test helps PlexusDx identify your likely response category, improving your chances of achieving meaningful results.

What is the cost of GLP-1 treatment at PlexusDx?

PlexusDx offers flat monthly pricing: Compounded Semaglutide Injection starts at $149/month, and Compounded Tirzepatide Injection starts at $249/month—your dose may increase, but your price won't. All options are HSA/FSA eligible with no insurance required or membership fees.

Are compounded GLP-1 medications as safe as FDA-approved versions?

Compounded semaglutide and tirzepatide from PlexusDx are manufactured in licensed 503A compounding pharmacies under strict state and federal oversight, containing identical active ingredients to brand-name products. Both compounded and FDA-approved versions carry the same safety profile and side effect risks.

How can the Precision Peptide Genetic Test improve my weight loss results?

The Precision Peptide Genetic Test examines 49 peptides across 14 metabolic pathways, including key variants like GLP1R rs6923761 and FTO rs9939609, to predict whether you'll respond best to semaglutide, tirzepatide, oral formulations, or combination therapy. This $99 test after your first month eliminates guesswork and personalizes your treatment plan based on your unique biology.

Are GLP-1 Approved for Weight Loss? Exploring the Latest in Weight Management